Key result
Elevated postprocedural levels of syndecan-1 (HR 1.986), troponin T (HR 1.316), and CRP (HR 1.036) independently predicted microvascular occlusion in STEMI patients after primary PCI.
Why the study?
Predictors of microvascular occlusion in patients with STEMI after primary PCI needed to be determined.
Are serum biomarkers associated with microvascular occlusion in patients with STEMI after primary PCI?
Observational (n=113)
No
Are serum biomarkers associated with microvascular occlusion in patients with STEMI after primary PCI?
Hazard Ratio: 1.986 (95% CI 1.279–3.082)
p-value: p=0.002
Elevated levels of CRP, TnT, and syndecan-1 measured 1 day after primary PCI are independent predictors of microvascular occlusion in STEMI patients.
CRP, TnT, and syndecan-1 levels were associated with post-pPCI MVO; leaves open their utility for risk stratification or guiding therapy.
OBJECTIVE: This study aimed to determine predictors of microvascular occlusion (MVO) in patients with ST elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (pPCI). METHODS: This retrospective, observational study consecutively included 113 patients with STEMI undergoing pPCI. Cardiac magnetic resonance imaging was used to determine the presence of MVO in these patients. Biomarkers in serum were routinely tested 1 day after pPCI. Multivariable logistic regression analysis was used to evaluate significant predictors of occurrence of MVO. RESULTS: There were 62 patients in the MVO group and 51 patients in the non-MVO group. C-reactive protein (CRP), thrombomodulin, lymphatic vessel endothelial hyaluronan receptor-1, syndecan-1, and troponin T (TnT) levels after the procedure were significantly higher in the MVO group than in the non-MVO group. CRP (hazard ratio [HR]=1.036), TnT (HR=1.316), and syndecan-1 (HR=1.986) levels were independently associated with MVO in patients with acute myocardial infarction after pPCI. CONCLUSIONS: Levels of CRP, TnT, and syndecan-1 can be used as serum biomarkers for MVO in patients with STEMI receiving pPCI.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted an observational in ST elevation myocardial infarction (STEMI) (n=113). Elevated serum biomarkers (syndecan-1, TnT, CRP) vs. Lower biomarker levels was evaluated on Microvascular occlusion (MVO) determined by cardiac magnetic resonance imaging (HR 1.986, 95% CI 1.279-3.082, p=0.002). Elevated postprocedural levels of syndecan-1 (HR 1.986), troponin T (HR 1.316), and CRP (HR 1.036) independently predicted microvascular occlusion in STEMI patients after primary PCI.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: